Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.

Source:http://linkedlifedata.com/resource/pubmed/id/12480706

Blood 2003 Apr 15 101 8 2960-2

Download in:

View as

General Info

PMID
12480706